Tokyo Tape
Sign in
← Vital Ksk Holdings

Quarterly report · Q1

3151.TEDINET S100OW8K
Period2022-04-01 → 2022-06-30
Filed2022-08-09
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
MetricValuePeriodScopeSource row
Revenue¥143.5bn2022-04-01 → 2022-06-30Cons.Net sales
Revenue¥577.2bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥142.9bn2021-04-01 → 2021-06-30Cons.Net sales
Operating income¥452m2022-04-01 → 2022-06-30Cons.Operating income
Operating income¥377m2021-04-01 → 2021-06-30Cons.Operating income
Ordinary income¥1.2bn2022-04-01 → 2022-06-30Cons.Ordinary income
Ordinary income¥5.8bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥1.1bn2021-04-01 → 2021-06-30Cons.Ordinary income
Profit before tax¥1.1bn2022-04-01 → 2022-06-30Cons.Income before income taxes
Profit before tax¥1.1bn2021-04-01 → 2021-06-30Cons.Income before income taxes
Net income (owners)¥640m2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥4.8bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥644m2021-04-01 → 2021-06-30Cons.Profit loss attributable to owners of parent
Net income¥675m2022-04-01 → 2022-06-30Cons.Profit loss
Net income¥674m2021-04-01 → 2021-06-30Cons.Profit loss
Total assets¥314.2bnat 2022-06-30Cons.Assets
Total assets¥313.0bnat 2022-03-31Cons.Assets
Total assets¥333.7bnat 2021-06-30Cons.Total assets (5-year summary)
Total liabilities¥212.9bnat 2022-06-30Cons.Liabilities
Total liabilities¥213.0bnat 2022-03-31Cons.Liabilities
Net assets / equity¥101.4bnat 2022-06-30Cons.Net assets
Net assets / equity¥100.0bnat 2022-03-31Cons.Net assets
Net assets / equity¥106.1bnat 2021-06-30Cons.Net assets (5-year summary)
Cash and deposits¥27.9bnat 2022-06-30Cons.Cash and deposits
Cash and deposits¥27.0bnat 2022-03-31Cons.Cash and deposits
EPS (basic)¥12.052022-04-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥87.882021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥11.672021-04-01 → 2021-06-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio31.9%at 2022-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio31.6%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio31.5%at 2021-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 54
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-06-30¥1.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-06-30¥1.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-06-30¥626m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-06-30−¥69m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-06-30−¥3.4bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-06-30−¥3.4bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-06-30¥0
jpcrp040300-q1r_E22440-000Medicine Wholesalereportable segmentrevenue2022-04-01 → 2022-06-30¥138.0bn
jpcrp040300-q1r_E22440-000Medicine Wholesalereportable segmentrevenue external2022-04-01 → 2022-06-30¥135.2bn
jpcrp040300-q1r_E22440-000Medicine Wholesalereportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥2.8bn
jpcrp040300-q1r_E22440-000Medicine Wholesalereportable segmentsegment profit2022-04-01 → 2022-06-30¥389m
jpcrp040300-q1r_E22440-000Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥4.5bn
jpcrp040300-q1r_E22440-000Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥4.5bn
jpcrp040300-q1r_E22440-000Pharmacy Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥0
jpcrp040300-q1r_E22440-000Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥14m
jpcrp040300-q1r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥2.7bn
jpcrp040300-q1r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥2.7bn
jpcrp040300-q1r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥0
jpcrp040300-q1r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥118m
—segment totalrevenue2022-04-01 → 2022-06-30¥145.1bn
—segment totalrevenue external2022-04-01 → 2022-06-30¥142.3bn
—segment totalrevenue intersegment2022-04-01 → 2022-06-30¥2.8bn
—segment totalsegment profit2022-04-01 → 2022-06-30¥521m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-06-30¥146.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-06-30¥143.5bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-06-30¥3.4bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-06-30¥452m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2021-04-01 → 2021-06-30¥1.7bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2021-04-01 → 2021-06-30¥1.1bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2021-04-01 → 2021-06-30¥626m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2021-04-01 → 2021-06-30−¥45m
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-06-30−¥2.8bn
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-06-30−¥2.8bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-06-30−¥13m
jpcrp040300-q1r_E22440-000Medicine Wholesalereportable segmentrevenue2021-04-01 → 2021-06-30¥137.0bn
jpcrp040300-q1r_E22440-000Medicine Wholesalereportable segmentrevenue external2021-04-01 → 2021-06-30¥134.8bn
jpcrp040300-q1r_E22440-000Medicine Wholesalereportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥2.2bn
jpcrp040300-q1r_E22440-000Medicine Wholesalereportable segmentsegment profit2021-04-01 → 2021-06-30¥290m
jpcrp040300-q1r_E22440-000Pharmacy Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥4.4bn
jpcrp040300-q1r_E22440-000Pharmacy Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥4.4bn
jpcrp040300-q1r_E22440-000Pharmacy Businessreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥1m
jpcrp040300-q1r_E22440-000Pharmacy Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥39m
jpcrp040300-q1r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥2.6bn
jpcrp040300-q1r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥2.6bn
jpcrp040300-q1r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥0
jpcrp040300-q1r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥106m
—segment totalrevenue2021-04-01 → 2021-06-30¥144.0bn
—segment totalrevenue external2021-04-01 → 2021-06-30¥141.8bn
—segment totalrevenue intersegment2021-04-01 → 2021-06-30¥2.2bn
—segment totalsegment profit2021-04-01 → 2021-06-30¥437m
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-06-30¥145.8bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-06-30¥142.9bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-06-30¥2.8bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-06-30¥391m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 370
ItemContextValueUnit
Income taxes payablePrior1YearInstant2399000000JPY
Income taxes payableCurrentQuarterInstant482000000JPY
Provision for bonusesPrior1YearInstant1542000000JPY
Provision for bonusesCurrentQuarterInstant2391000000JPY
Other clPrior1YearInstant7505000000JPY
Other clCurrentQuarterInstant9457000000JPY
Current liabilitiesPrior1YearInstant190092000000JPY
Current liabilitiesCurrentQuarterInstant191527000000JPY
Long term loans payablePrior1YearInstant7760000000JPY
Long term loans payableCurrentQuarterInstant7517000000JPY
Other provision nclPrior1YearInstant244000000JPY
Other provision nclCurrentQuarterInstant243000000JPY
Net defined benefit liabilityPrior1YearInstant2629000000JPY
Net defined benefit liabilityCurrentQuarterInstant516000000JPY
Other nclPrior1YearInstant12265000000JPY
Other nclCurrentQuarterInstant13054000000JPY
Noncurrent liabilitiesPrior1YearInstant22898000000JPY
Noncurrent liabilitiesCurrentQuarterInstant21332000000JPY
LiabilitiesPrior1YearInstant212991000000JPY
LiabilitiesCurrentQuarterInstant212859000000JPY
Capital stockPrior1YearInstant5000000000JPY
Capital stockCurrentQuarterInstant5000000000JPY
Capital surplusPrior1YearInstant12810000000JPY
Capital surplusCurrentQuarterInstant12810000000JPY
Retained earningsPrior1YearInstant64402000000JPY
Retained earningsCurrentQuarterInstant64296000000JPY
Treasury stockPrior1YearInstant-6581000000JPY
Treasury stockCurrentQuarterInstant-7578000000JPY
Shareholders equityPrior1YearInstant75631000000JPY
Shareholders equityCurrentQuarterInstant74527000000JPY
Valuation difference on available for sale securitiesPrior1YearInstant21645000000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant24127000000JPY
Remeasurements of defined benefit plansPrior1YearInstant1683000000JPY
Remeasurements of defined benefit plansCurrentQuarterInstant1593000000JPY
Valuation and translation adjustmentsPrior1YearInstant23329000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant25721000000JPY
Non controlling interestsPrior1YearInstant1080000000JPY
Non controlling interestsCurrentQuarterInstant1112000000JPY
Net assetsPrior1YearInstant100041000000JPY
Net assetsCurrentQuarterInstant101361000000JPY
Liabilities and net assetsPrior1YearInstant313033000000JPY
Liabilities and net assetsCurrentQuarterInstant314221000000JPY
Net salesPrior1YTDDuration142916000000JPY
Net salesCurrentYTDDuration143521000000JPY
Cost of salesPrior1YTDDuration132694000000JPY
Cost of salesCurrentYTDDuration132786000000JPY
Gross profitPrior1YTDDuration10221000000JPY
Gross profitCurrentYTDDuration10735000000JPY
Gross profit net gpPrior1YTDDuration10221000000JPY
Gross profit net gpCurrentYTDDuration10735000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-06-30pass